BeiGene pipeline at a glance (March 2026)
About the BeiGene clinical program
BeiGene has emerged as one of the most significant oncology-focused biopharmaceuticals globally, with particular strength in B-cell malignancies and solid tumor targeted therapy. Brukinsa (zanubrutinib) is a next-generation covalent BTK inhibitor with superior CNS penetration and more complete BTK occupancy than first-generation ibrutinib — it has become one of the fastest-growing hematology drugs globally, with approvals across CLL/SLL, Waldenström's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. Tislelizumab, their PD-1 checkpoint inhibitor, is approved in multiple indications in China and is advancing through global registrations. BeiGene's solid tumor pipeline includes a KRAS G12C inhibitor and multiple investigational combinations across gastrointestinal and thoracic malignancies.
Key therapeutic areas
- Hematology (CLL, MCL, WM, marginal zone lymphoma)
- BTK inhibition (B-cell malignancies)
- Solid tumors (PD-1, KRAS G12C, TIGIT)
- Gastrointestinal oncology
- Global clinical development (China + international)
Key pipeline programs
- Brukinsa (zanubrutinib) — next-gen BTK, CLL/SLL/MCL/WM
- Tislelizumab — PD-1, multiple solid tumors and hematology
- BGB-10188 — PI3Kδ inhibitor, B-cell malignancies
- BGB-3245 — BRAF inhibitor, RAF-altered cancers
- Sonrotoclax — BCL-2 inhibitor, hematologic malignancies
- BGB-A445 — OX40 agonist, solid tumors
Monitor the BeiGene pipeline daily
Get alerts when BeiGene registers new trials or updates existing protocols. Free 14-day trial — no credit card required.
Start Monitoring FreeTop BeiGene trial indications
| Condition / Indication | Trials |
|---|---|
| ["Advanced Solid Tumor"] | 3 |
| ["Non Small Cell Lung Cancer"] | 2 |
| ["Solid Tumor, Adult"] | 2 |
| ["Relapsed/Refractory Follicular Lymphoma", "Marginal Zone Lymphoma"] | 1 |
| ["Rheumatoid Arthritis"] | 1 |
| ["Ovarian Cancer"] | 1 |
| ["Non-small Cell Lung Cancer", "Metastatic Non-small Cell Lung Cancer"] | 1 |
| ["Relapsed/Refractory Follicular Non-Hodgkin Lymphoma"] | 1 |
Why monitor BeiGene's clinical trial activity
BeiGene's Brukinsa (zanubrutinib) continues expanding its CLL and MCL label — combination trials with BCL-2 inhibitors (sonrotoclax) and CD20 antibodies are among the most actively followed in hematology BD. Their BCL-2 inhibitor sonrotoclax is a direct competitor to venetoclax, making BeiGene's trial registrations critical competitive intelligence for Roche and AbbVie.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to BeiGene's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.
How DataLookout tracks BeiGene trials
- Sponsor normalization: BeiGene may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your BeiGene pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Start Free TrialFrequently asked questions
What is BeiGene's focus in hematology clinical trials?
BeiGene's hematology pipeline is centered on Brukinsa (zanubrutinib), their next-generation BTK inhibitor, with expansion trials in CLL, MCL, WM, and marginal zone lymphoma — plus combination studies with BCL-2 inhibitor sonrotoclax and PI3Kδ inhibitor BGB-10188. Their sonrotoclax program directly competes with AbbVie/Roche's venetoclax in the CLL space.
How many BeiGene trials are currently recruiting?
Based on current ClinicalTrials.gov data, 12 BeiGene-sponsored trials are actively recruiting patients. Note that BeiGene registers many studies under Chinese regulatory systems in addition to ClinicalTrials.gov — global counts may be higher.
Can DataLookout track BeiGene's BTK inhibitor trial updates?
Yes. DataLookout monitors ClinicalTrials.gov for all BeiGene-registered trials, including Brukinsa combination studies, tislelizumab expansion trials, and earlier-stage pipeline registrations. Set a BeiGene watchlist to receive daily alerts on new registrations and status changes.